Japan Medical Dynamic Marketing, INC.
Stock Price Chart
2026/11/20 13:29 UpdatedPrice Trend
2026/11/20 13:29 UpdatedPrice & Trading Details
2026/11/20 13:29 UpdatedPRICE
TRADING
Shareholder Composition
Updated 2026/11/01Top Mutual Funds / ETFs
Updated 2026/11/01Major Holders
Updated 2026/11/01| Fund Name | Ownership | Shares | Change |
|---|---|---|---|
|
Dimensional ETF Trust-Dimensional International Small Cap Value ETF
|
61.0K | +2.07% | |
|
DFA INVESTMENT DIMENSIONS GROUP INC-DFA Intl Small Cap Value PORT.
|
57.4K | 0.00% | |
|
DFA INVESTMENT TRUST CO-The Japanese Small Company Series
|
46.9K | +78.32% | |
|
Dimensional ETF Trust-Dimensional International Core Equity 2 ETF
|
37.3K | +48.60% | |
|
Dimensional ETF Trust-Dimensional International Small Cap ETF
|
29.1K | +6.99% | |
|
DFA INVESTMENT DIMENSIONS GROUP INC-Intl Core Eqy. 2 PORT.
|
27.5K | +46.96% |
Dividend History 4Years Growth
Updated 2026/11/22| Year | Dividend | Change |
|---|---|---|
| 2026 | ¥17 | +13.3% |
| 2025 | ¥15 | +7.1% |
| 2024 | ¥14 | +7.7% |
| 2023 | ¥13 | +8.3% |
| 2022 | ¥12 | - |
Financial Performance
2026/11/22 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥21,308M | ¥23,178M | ¥25,114M | ¥23,917M |
| Gross Profit | ¥13,993M | ¥14,762M | ¥15,647M | ¥14,142M |
| Operating Income | ¥2,025M | ¥1,747M | ¥1,556M | ¥574M |
| Pretax Income | ¥1,788M | ¥1,669M | -¥267M | ¥694M |
| Net Income | ¥1,424M | ¥1,272M | -¥462M | ¥263M |
| EPS | ¥54.03 | ¥48.31 | -¥17.50 | ¥9.99 |
| Operating Margin | 9.50% | 7.54% | 6.20% | 2.40% |
| Balance Sheet | ||||
| Total Assets | ¥29,435M | ¥31,486M | ¥33,667M | ¥35,679M |
| Total Equity | ¥23,162M | ¥25,511M | ¥24,679M | ¥25,400M |
| Total Liabilities | ¥6,273M | ¥5,975M | ¥8,988M | ¥10,279M |
| Cash | ¥2,805M | ¥2,322M | ¥3,182M | ¥3,107M |
| Interest-bearing Debt | ¥1,872M | ¥1,494M | ¥3,287M | ¥5,871M |
| Equity Ratio | 78.69% | 81.02% | 73.30% | 71.19% |
| D/E Ratio | 0.08 | 0.06 | 0.13 | 0.23 |
| Cash Flow | ||||
| Operating CF | ¥2,186M | ¥2,105M | ¥1,047M | ¥206M |
| Investing CF | -¥1,482M | -¥1,805M | -¥1,667M | -¥1,996M |
| Financing CF | -¥515M | -¥841M | ¥1,490M | ¥1,649M |
| Free CF | ¥871M | ¥302M | -¥620M | -¥1,792M |
| Efficiency | ||||
| ROE | 6.15% | 4.98% | -1.87% | 1.04% |
| ROA | 4.84% | 4.04% | -1.37% | 0.74% |
Latest IR Information
-
Notice of Approval for Market Segment Change to the Tokyo Stock Exchange Standard Market and Withdrawal of the Plan to Meet Prime Market Listing Maintenance Criteria
Although approval was received to change the market segment, the plan to meet Prime Market criteria has been withdrawn. Going forward, the Company will aim to enhance corporate value through improved profitability, capital efficiency, and strengthened IR following the transition...
Read more -
Earnings Presentation First Half of Fiscal Year Ending March 2027
Consolidated revenue for the first half was 10,437 million yen (YoY -10.1%), and operating loss widened to -103.6 hundred million yen. The primary causes were revenue decline and cost deterioration in the U.S. market. Full-year forecasts were revised and the...
Read more -
November 4, 2026 Notice Regarding Differences Between Actual Results and Fiscal Year Ending March 2027 Second Quarter Consolidated Earnings Forecast, Revision of Full-Year Consolidated Earnings Forecast, Recognition of Adjustment for Corporate Taxes and Dividend Forecast Revision
Full-year earnings forecast has been significantly revised to net sales of 21,700 million yen, operating loss of -1,500 million yen, and net loss of -2,500 million yen attributable to owners of the parent. Second-quarter results fell short of prior forecasts,...
Read more -
Financial Summary for the Second Quarter (Interim) of the Fiscal Year Ending March 2027
Consolidated results for the second quarter of the fiscal year ending March 2027: net sales 10,437 million yen, operating loss 1,036 million yen, interim net loss attributable to owners of parent 1,749 million yen. Cost of sales ratio rose to...
Read more -
Notice Regarding Clarification of Management Responsibility and Promotion of Performance Improvement Plan
Revised downward full-year and second-quarter performance forecasts. To clarify management responsibility, substantial reductions in executive compensation including the President, and voluntary compensation returns by independent outside directors will be implemented. Promote structural reform of U.S. subsidiary ODEV and company-wide cost...
Read more
Latest News (5 items)
Company Information
About
Japan Medical Dynamic Marketing, INC. develops, manufactures, imports, and sells medical devices in Japan and the United States. The company provides trauma devices, including nails, screws, plates, and other products surgically implanted in the fracture site used in surgery to treat femoral neck fractures, most often suffered by the elderly, and other fractures from auto-related and other accidents; joint prostheses, which replaces natural joints and restores functions damaged or lost due to disease or injury, such as hip and knee joint products; spinal fixation devices to fix spinal instability directly through corrective surgery; and artificial bones that are used to fill gaps in bone defects caused by bone fractures or bone tumors. It offers its products to doctors, medical institutions, and hospitals. The company was incorporated in 1973 and is headquartered in Shinjuku, Japan.